Inflammation and therapy for hypertension

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 233-242

  Laffer, Cheryl L ^a   Elijovich, Fernando ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Antihypertensive agents; Beta blockers; Blockers of the renin angiotensin system; Calcium channel blockers; Cytokines; Endothelin receptor blockers; Hypertension; Inflammation; Mineralocorticoid receptor blockers; Oxidative stress; Thiazides

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFONIDIPINE; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENALINE; LISINOPRIL; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; QUINAPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; COLLAGEN DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DISORDER; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLEIOTROPY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CYTOKINES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, ENDOTHELIN; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; THIAZIDES;

EID: 77956264997     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0125-3     Document Type: Review

References (75)

1. CL Laffer RJ Bolterman JC Romero F Elijovich 2006 Effect of salt on isoprostanes in salt-sensitive essential hypertension Hypertension 47 434 440 10.1161/01.HYP.0000202480.06735.82 1:CAS:528:DC%2BD28Xht1Cmtr0%3D 16432053
2. ST Rahman WB Lauten QA Khan, et al. 2002 Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation) Am J Cardiol 89 686 690 10.1016/S0002-9149(01)02340-2 1:CAS:528: DC%2BD38XhvVWktbc%3D 11897210
3. JW Eriksson PA Jansson B Carlberg, et al. 2008 Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) study Hypertension 52 1030 1037 10.1161/HYPERTENSIONAHA. 108.119404 1:CAS:528:DC%2BD1cXhsVWrt7jJ 18981327
4. MT Schram FJ van Ittersum A Spoelstra-de Man, et al. 2005 Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial J Hum Hypertens 19 429 437 10.1038/sj.jhh.1001812 1:CAS:528:DC%2BD2MXkt1CktL0%3D 15647778
5. J Loffing D Loffing-Cueni I Hegyi, et al. 1996 Thiazide treatment of rats provokes apoptosis in distal tubule cells Kidney Int 50 1180 1190 10.1038/ki.1996.426 1:CAS:528:DyaK28Xmt1Kqu7w%3D 8887276
6. B Westendorp I Hamming MK Szymanski, et al. 2009 Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor Eur J Pharmacol 602 373 379 10.1016/j.ejphar.2008.11.055 1:CAS:528:DC%2BD1MXksVajug%3D%3D 19084001
7. SU Monrad PD Killen MR Anderson, et al. 2008 The role of aldosterone blockade in murine lupus nephritis Arth Res Ther 10 R5 10.1186/ar2353 Using a murine model of an autoimmune inflammatory disease, unrelated to blood pressure, the authors document an inflammatory role for aldosterone by demonstrating that spironolactone decreases expression of inflammatory genes and ameliorates proteinuria and renal damage
8. A Syngle K Vohra L Kaur S Sharma 2009 Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis Scand J Rheumatol 38 15 22 10.1080/03009740802279709 1:CAS:528:DC%2BD1MXhsFWntb8%3D 18766955
9. R Rocha CL Martin-Berger P Yang, et al. 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart Endocrinology 143 4828 4836 10.1210/en.2002-220120 1:CAS:528: DC%2BD38Xpt1eltLs%3D 12446610
10. JM Luther JV Gainer LJ Murphey, et al. 2006 Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism Hypertension 48 1050 1057 10.1161/01.HYP.0000248135.97380.76 1:CAS:528:DC%2BD28XhtFymt7fK 17043157
11. K Nagata K Obata J Xu, et al. 2006 Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats Hypertension 47 656 664 10.1161/01.HYP.0000203772.78696.67 1:CAS:528: DC%2BD28XitlSgtLo%3D 16505208
12. DA Calhoun D Jones S Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the Council for High Blood Pressure Research Hypertension 51 1403 1419 10.1161/HYPERTENSIONAHA.108.189141 1:CAS:528:DC%2BD1cXlvFaitLw%3D 18391085
13. NA Turner KE Porter WH Smith, et al. 2003 Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism Cardiovasc Res 57 784 792 10.1016/S0008-6363(02)00729-0 1:CAS:528:DC%2BD3sXhs1ehtrg%3D 12618240
14. H Kiriazis K Wang Q Xu, et al. 2008 Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis Br J Pharmacol 153 684 692 10.1038/sj.bjp.0707622 1:CAS:528:DC%2BD1cXitVKjsL8%3D 18193078 Knocking out the beta-adrenergic receptors in mice, the authors showed that these animals are protected from the LVH and increased cardiac inflammatory cytokines, fibrogenic growth factors, and fibrosis that aortic banding induces in wild-type mice. This finding documents that inflammatory signaling pathways triggered by beta-receptor activation participate in cardiac hypertrophy secondary to pressure overload
15. B Mayer SR Holmer C Hengstenberg, et al. 2005 Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels Int J Cardiol 103 182 186 10.1016/j.ijcard.2004.08.053 16080978
16. M Nishio Y Sakata T Mano, et al. 2008 Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats Eur J Heart Fail 10 446 453 10.1016/j.ejheart.2008.03.002 1:CAS:528:DC%2BD1cXls1yqurw%3D 18400557
17. L Rossig J Haendeler Z Mallat, et al. 2000 Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol J Am Coll Cardiol 36 2081 2089 10.1016/S0735-1097(00)01002-0 1:CAS:528: DC%2BD3cXptFSqtLo%3D 11127444
18. S Chua JJ Sheu LT Chang, et al. 2008 Comparison of losartan and carvedilol on attenuating inflammatory and oxidative response and preserving energy transcription factors and left ventricular function in dilated cardiomyopathy rats Int Heart J 49 605 619 10.1536/ihj.49.605 1:CAS:528:DC%2BD1cXhsVSjurjO 18971572
19. LH Lindholm B Carlberg O Samuelsson 2005 Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 1545 1453 10.1016/S0140-6736(05)67573-3 1:CAS:528:DC%2BD2MXhtFKhsbfI 16257341
20. C Savoia RM Touyz F Amiri EL Schiffrin 2008 Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients Hypertension 51 432 439 10.1161/HYPERTENSIONAHA.107.103267 1:CAS:528:DC%2BD1cXotlSrug%3D%3D 18195160
21. V Fonseca GL Bakris DS Bell, et al. 2007 Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI Diabet Med 24 759 763 10.1111/j.1464-5491.2007.02151.x 1:CAS:528:DC%2BD2sXptFGnsrs%3D 17451422
22. E Rizos E Bairaktari A Kostoula, et al. 2003 The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study J Cardiovasc Pharmacol Ther 8 127 134 10.1177/107424840300800206 1:CAS:528:DC%2BD3sXltlKitb8%3D 12808486
23. G Iaccarino V Trimarco F Lanni, et al. 2005 β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene Pharmacogenomics J 5 292 297 10.1038/sj.tpj.6500324 1:CAS:528: DC%2BD2MXhtVehsL7F 16027735
24. M Fasshauer J Klein S Neumann, et al. 2001 Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes FEBS Lett 500 60 63 10.1016/S0014-5793(01)02588-1 1:CAS:528:DC%2BD3MXkvVemu7Y%3D 11434927
25. SC Wolf G Sauter M Preyer, et al. 2007 Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells: effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol Cell Physiol Biochem 19 129 136 10.1159/000099201 1:CAS:528:DC%2BD2sXhs1Crur8%3D 17310107
26. C Gandhi R Zalawadia R Balaraman 2008 Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats Ren Fail 30 921 930 10.1080/08860220802353900 1:CAS:528:DC%2BD1cXht1KntbrE 18925533
27. AC Schmidt B Flick E Jahn P Bramlage 2008 Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers Vasc Health Risk Manag 4 909 915 1:CAS:528:DC%2BD1cXht1ShurzK 19066009 This small study in human volunteers indicates that the unique NO synthase stimulatory activity of the novel beta-blocker nebivolol has functional significance in humans-hence, the potential for beneficial effects beyond blood pressure reduction, yet to be documented in clinical trials
28. ER Mohler LC Sorensen JK Ghali, et al. 1997 Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. (Prospective Randomized Amlodipine Survival Evaluation) J Am Coll Cardiol 30 35 41 10.1016/S0735-1097(97)00145-9 1:CAS:528:DyaK2sXks1Kqsrk%3D 9207618
29. Y Hirooka Y Kimura M Nozoe, et al. 2006 Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats Hypertens Res Clin Exp 29 49 56 10.1291/hypres.29.49 1:CAS:528:DC%2BD28XjslahtrY%3D
30. MS Zhou EA Jaimes L Raij 2004 Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats Am J Hypertens 17 167 171 10.1016/j.amjhyper.2003.09.007 1:CAS:528: DC%2BD2cXmvF2nsQ%3D%3D 14751660
31. H Toba T Shimizu S Miki, et al. 2006 Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells Hypertens Res 29 105 116 10.1291/hypres.29.105 1:CAS:528:DC%2BD28XltFeru7s%3D 16755144
32. YK On CH Kim DW Sohn, et al. 2002 Improvement of endothelial function by amlodipine and vitamin C in essential hypertension Korean J Intern Med 17 131 137 1:CAS:528:DC%2BD38XmsVWltb0%3D 12164090
33. T Yoshii M Iwai Z Li, et al. 2006 Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions Hypertens Res 29 457 466 10.1291/hypres.29.457 1:CAS:528:DC%2BD28Xpt1ynsLc%3D 16940709
34. JL Martin-Ventura B Munoz-Garcia LM Blanco-Colio, et al. 2008 Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis Kidney Int Suppl 74 S71 S74 10.1038/ki.2008.521
35. M Anjaneyulu K Chopra 2005 Diltiazem attenuates oxidative stress in diabetic rats Ren Fail 27 335 344 1:CAS:528:DC%2BD2MXks1ehtrs%3D 15957552
36. T Matsui S Yamagishi M Takeuchi, et al. 2009 Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation Biochem Biophys Res Commun 385 269 272 10.1016/j.bbrc.2009.05.061 1:CAS:528:DC%2BD1MXntVGmuro%3D 19460355
37. J Li QX Li XF Xie, et al. 2009 Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats Eur J Pharmacol 620 97 104 10.1016/j.ejphar. 2009.08.021 1:CAS:528:DC%2BD1MXhtFGlt7rJ 19698708 Despite lack of benefit by DHP CCBs in the progression of human renal disease, some of these agents exhibit anti-inflammatory and antioxidant effects in experimental models of aminoglycoside-induced nephropathy, perhaps explaining newer observations in which their protective effects on human kidney can be unmasked by combination with blockers of the RAS [40••]
38. SR Orth R Nobiling S Bonisch E Ritz 1996 Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels Kidney Int 49 868 879 10.1038/ki.1996.120 1:CAS:528:DyaK28Xkslantrg%3D 8648932
39. S Nathan CJ Pepine GL Bakris 2005 Calcium antagonists: effects on cardio-renal risk in hypertensive patients Hypertension 46 637 642 10.1161/01.HYP.0000184541.24700.c7 1:CAS:528:DC%2BD2MXhtV2hsbfL 16172420
40. GL Bakris PA Sarafidis MR Weir, et al. 2010 Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial Lancet 375 1173 1181 10.1016/S0140-6736(09)62100-0 1:CAS:528:DC%2BC3cXktlGitr8%3D 20170948 This is recent evidence demonstrating greater renal protection by combining a blocker of the RAS with a DHP CCB, compared with combining a blocker of the RAS with a thiazide diuretic in hypertensive patients. This finding suggests that once the potentially detrimental effect of afferent arteriolar vasodilation by DHPs is counteracted by blockade of the RAS, the pleiotropic effects of DHPs [37•] are unmasked
41. YY Fan M Kohno D Nakano, et al. 2009 Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats J Hypertens 27 1855 1862 10.1097/HJH.0b013e32832dda6f 1:CAS:528: DC%2BD1MXhtVWhsr%2FM 19633569
42. S Inaba M Iwai Y Tomono, et al. 2009 Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists Am J Hypertens 22 145 150 10.1038/ajh.2008.344 1:CAS:528: DC%2BD1MXotVKjsw%3D%3D 19057515
43. K Nakano K Egashira K Ohtani, et al. 2008 Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice Atherosclerosis 196 172 179 10.1016/j.atherosclerosis.2007. 03.036 1:CAS:528:DC%2BD1cXpt1yrug%3D%3D 17481639
44. S Ogawa T Mori K Nako S Ito 2008 Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy Hypertens Res 31 1147 1155 10.1291/hypres.31.1147 1:CAS:528:DC%2BD1cXhtFaqsbfK 18716362
45. M Matsubara O Akizuki J Ikeda, et al. 2008 Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats Eur J Pharmacol 580 201 213 10.1016/j.ejphar. 2007.10.072 1:CAS:528:DC%2BD1cXlt1ehsg%3D%3D 18048030
46. H Sasaki A Saiki K Endo, et al. 2009 Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy J Atheroscler Thromb 16 568 575 1:CAS:528:DC%2BD1MXhsV2jtrrP 19749494
47. K Takemori H Ishida K Dote, et al. 2005 Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats Can J Physiol Pharmacol 83 785 790 10.1139/y05-067 1:CAS:528:DC%2BD2MXht12ntLfI 16333380
48. S Taddei A Virdis L Ghiadoni, et al. 2003 Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension Hypertension 41 950 955 10.1161/01.HYP.0000063361.70525.3C 1:CAS:528:DC%2BD3sXitlKgs70%3D 12642509
49. D Cai M Yuan DF Frantz, et al. 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB Nat Med 11 183 190 10.1038/nm1166 1:CAS:528:DC%2BD2MXpvF2ntQ%3D%3D 15685173
50. SE Shoelson J Lee M Yuan 2003 Inflammation and the IKK-beta/I-kappaB/NF- kappaB axis in obesity- and diet-induced insulin resistance Int J Obes Relat Metab Disord 27 S49 S52 10.1038/sj.ijo.0802501 1:CAS:528:DC%2BD2cXls1Kj 14704745
51. RT Cowling D Gurantz J Peng, et al. 2002 Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta J Biol Chem 277 5719 5724 10.1074/jbc.M107515200 1:CAS:528: DC%2BD38XhvFyrs7c%3D 11600498
52. A Schmeisser O Soehnlein T Illmer, et al. 2004 ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression Biochem Biophys Res Commun 325 532 540 10.1016/j.bbrc.2004.10.059 1:CAS:528:DC%2BD2cXpsVOlsL0%3D 15530425
53. PC Cristovam CP Arnoni MC de Andrade, et al. 2008 ACE- and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells Exp Biol Med 233 1035 1043 10.3181/0708-RM-229 1:CAS:528:DC%2BD1cXptlaltLY%3D
54. O Costerousse J Allegrini J Clozel, et al. 1988 Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia J Pharmacol Exp Ther 284 1180 1187
55. I Ignjacev-Lazich E Kintsurashvili C Johns, et al. 2005 Angiotensin-converting enzyme regulates bradykinin receptor gene expression Am J Physiol Heart Circ Physiol 289 H1814 H1820 10.1152/ajpheart.00581.2005 1:CAS:528:DC%2BD2MXht1Cnt7jP 16219810
56. S Frantz D Fraccarollo H Wagner, et al. 2003 Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure Cardiovasc Res 57 749 756 10.1016/S0008-6363(02)00723-X 1:CAS:528: DC%2BD3sXhs1ehtrw%3D 12618236
57. HX Xu JJ Li GS Li, et al. 2007 Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan Acta Cardiol 62 607 613 10.2143/AC.62.6.2024021 18214127
58. V Esteban M Ruperez JR Vita, et al. 2003 Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response Kidney Int 86 S33 S38 10.1046/j.1523-1755.64.s86.7.x 1:CAS:528: DC%2BD3sXot1Wisrk%3D
59. O Lorenzo M Ruiz-Ortega Y Suzuki, et al. 2002 Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice J Am Soc Nephrol 13 1162 1171 10.1097/01.ASN.0000015622.33198.BF 1:CAS:528:DC%2BD38XktFaisbw%3D 11961003
60. V Esteban M Ruperez E Sanchez-Lopez, et al. 2005 Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells Circ Res 96 965 973 10.1161/01.RES.0000166326. 91395.74 1:CAS:528:DC%2BD2MXjvFyntrs%3D 15831814
61. VP Singh B Le R Khode, et al. 2008 Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis Diabetes 57 3297 3306 10.2337/db08-0805 1:CAS:528:DC%2BD1MXhsleitrs%3D 18829990 Work in this laboratory has unequivocally documented activation of an intracellular RAS in experimental diabetes. They show here that increased generation of cardiomyocyte Ang II cannot be blocked by either an ACE inhibitor or an ARB but is effectively blocked by the direct renin inhibitor aliskiren, which was able to suppress superoxide production and fibrosis. This observation is important because it suggests that newer modalities in the blockade of the RAS may be more effective in preventing Ang II-induced insulin resistance, diabetes, or diabetic target organ damage
62. NDL Fisher AHJ Danser J Nussberger, et al. 2008 Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans Circulation 117 3199 3205 10.1161/CIRCULATIONAHA.108.767202 1:CAS:528: DC%2BD1cXnt1ehs70%3D 18559696
63. H Krum RJ Viskoper Y Lacourciere, et al. 1998 The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension N Engl J Med 338 784 791 10.1056/NEJM199803193381202 1:CAS:528:DyaK1cXitlChtbs%3D 9504938
64. MA Weber H Black G Bakris, et al. 2009 A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomized, double-blind, placebo-controlled trial Lancet 374 1423 1431 10.1016/S0140-6736(09)61500-2 1:CAS:528:DC%2BD1MXhtlSru7jK 19748665
65. C Fernandez-Patron C Zouki R Whittal, et al. 2001 Matrix metalloproteinases regulate neutrophil endothelial cell adhesion through generation of endothelin-1[1-32] FASEB J 15 2230 2240 10.1096/fj.01-0178com 1:CAS:528:DC%2BD3MXnsV2mtrg%3D 11641250
66. SH Wilson RD Simari A Lerman 2001 The effect of endothelin-1 on nuclear factor kappa B in macrophages Biochem Biophys Res Commun 286 968 972 10.1006/bbrc.2001.5485 1:CAS:528:DC%2BD3MXmtlejt7s%3D 11527395
67. Q Pu MF Neves A Virdis, et al. 2003 Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling Hypertension 42 49 55 10.1161/01.HYP.0000078357.92682.EC 1:CAS:528:DC%2BD3sXkvVKmtrk%3D 12782645
68. EI Boesen JM Sasser MA Saleh, et al. 2008 Interleukin-1β, but not interleukin-6, enhances renal and systemic endothelin production in vivo Am J Physiol Renal Physiol 295 F446 F453 10.1152/ajprenal.00095.2008 1:CAS:528:DC%2BD1cXhtVaktL%2FP 18524861
69. F Elijovich CL Laffer 2002 Participation of renal and circulating endothelin in salt-sensitive essential hypertension J Hum Hypertens 16 459 467 10.1038/sj.jhh.1001419 1:CAS:528:DC%2BD38XkslKnu7o%3D 12080429
70. F Elijovich CL Laffer EN Amador, et al. 2001 Regulation of plasma endothelin by salt in salt-sensitive hypertension Circulation 103 263 268 1:CAS:528:DC%2BD3MXhtFaisLY%3D 11208687
71. F Amiri P Paradis TL Reudelhuber EL Schiffrin 2008 Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells J Hypertens 26 1102 1109 10.1097/HJH. 0b013e3282fc2184 1:CAS:528:DC%2BD1cXlslGlsL4%3D 18475147
72. F Elijovich CL Laffer EL Schiffrin, et al. 2004 Endothelin-aldosterone interaction and proteinuria in low-renin essential hypertension J Hypertens 22 573 582 10.1097/00004872-200403000-00021 1:CAS:528:DC%2BD2cXjt1Sks70%3D 15076164
73. N Dhaun IM MacIntyre V Melville, et al. 2009 Blood pressure independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease Hypertension 54 113 119 10.1161/HYPERTENSIONAHA.109.132670 1:CAS:528:DC%2BD1MXntVyrtL0%3D 19506099
74. AC Montezano GE Callera A Yogi, et al. 2008 Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways Arterioscler Thromb Vasc Biol 28 1511 1518 10.1161/ATVBAHA.108.168021 1:CAS:528:DC%2BD1cXosVerurk%3D 18467645
75. E Bussemaker K Herbrig F Pistrosch, et al. 2009 Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients Atherosclerosis 207 567 572 10.1016/j.atherosclerosis.2009.05.025 1:STN:280:DC%2BD1MjosVeluw%3D%3D 19717154 This is an example of the application of a strategy of drug development that primarily targets a human signaling pathway involved in the control of vascular tone, and constitutes a new modality for the treatment of hypertension or its target organ consequences